Business Context and Reporting Period
This Form 6-K filing by GSK plc (GSK) is a transaction notification dated June 23, 2023. The report discloses a specific securities transaction involving a Person Discharging Managerial Responsibilities (PDMR) rather than providing periodic financial results.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. It solely reports on a single share purchase transaction:
- Instrument: Ordinary Shares of 31 pence each (ISIN: GB00BN7SWP63).
- Transaction Type: Purchase.
- Volume: 6,000 shares.
- Price: £14.3979 per share.
- Total Value: Approximately £86,387.40 (calculated from volume and price).
- Exchange: London Stock Exchange (XLON).
Material Changes
The filing does not contain comparative financial data or material changes to the company's operational performance versus prior periods. The only reported change is the increase in shareholding by the disclosed individual.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It is a statutory disclosure of a director's trading activity.
Key Facts for Investor Verification
- Insider Activity: Sir Jonathan Symonds, Non-Executive Chair, purchased 6,000 shares on June 23, 2023.
- Transaction Price: The purchase was executed at £14.3979 per share.
- Scope Limitation: This document does not contain GSK's quarterly or annual financial performance data; investors should refer to Form 20-F or earnings releases for financial metrics.